Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00273884 · ClinicalTrials.gov registry record · Phase 2
Amonafide in Combination With Cytarabine in Secondary AML
A Phase 2 study, sponsored by Xanthus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00273884: Completed Phase 2 study, sponsored by Xanthus Pharmaceuticals.
NCT00273884 is a Phase 2 study that has completed, run by Xanthus Pharmaceuticals. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00273884, a Phase 2 study, has completed, sponsored by Xanthus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
Interventions
- DRUG Cytarabine
- DRUG Amonafide L-Malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00273884 record still lists
NCT00273884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT00273884 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00273884 about?
NCT00273884 is a clinical study titled "Amonafide in Combination With Cytarabine in Secondary AML". This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
What is the current status of trial NCT00273884?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00273884?
The interventions under investigation include: Cytarabine (DRUG), Amonafide L-Malate (DRUG).
Who is sponsoring clinical trial NCT00273884?
This trial is sponsored by Xanthus Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00273884's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia